Protalix grants Naos 112K options, 56K RSUs

PLX’s senior vice president and COO received new stock options and RSUs that vest quarterly over three years.

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) reported that senior vice president and chief operating officer Yaron Naos received new equity awards on September 3, 2026. He was granted options to buy 112,000 shares of common stock at an exercise price of $2.59 per share, expiring on September 3, 2036, vesting in 12 equal quarterly installments starting on the grant date. He also received 56,000 restricted stock units, each representing one share of common stock, which vest in 12 equal quarterly installments commencing on the grant date. Footnotes state that these figures do not include several existing option grants with different exercise prices and expiration dates.

Insider Trade Summary

Grant/Award: 168,000 shares

Grant/Award 2 txns

Insider Naos Yaron

Role Sr. VP & COO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	112,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F3, F4	56,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 112,000 contracts (Direct); Restricted Stock Units — 56,000 contracts (Direct)

Footnotes (4)

1. F1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
2. F2. Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
3. F3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
4. F4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Key Figures

New stock options granted: 112,000 shares Option exercise price: $2.59 per share Option expiration date: September 3, 2036 +4 more

7 metrics

New stock options granted 112,000 shares Grant to Yaron Naos on September 3, 2026

Option exercise price $2.59 per share Exercise price for the 112,000 new options granted September 3, 2026

Option expiration date September 3, 2036 Expiration of 112,000-share option grant to Yaron Naos

Restricted stock units granted 56,000 units RSU grant to Yaron Naos on September 3, 2026

Vesting schedule for new awards 12 equal quarterly installments Applies to both the 112,000 options and 56,000 RSUs granted on September 3, 2026

Existing option grant 1 60,000 shares at $5.60, expiring September 13, 2028 Referenced in footnote as an additional option position

Existing option grant 2 340,000 shares at $1.03, expiring September 7, 2032 Referenced in footnote as an additional option position

Key Terms

restricted stock unit, stock options, exercise price, vesting

4 terms

restricted stock unit financial

"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

stock options financial

"The shares of common stock underlying the stock options vest in 12 equal quarterly installments"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What equity awards did PLX grant to Yaron Naos in this Form 4?

Yaron Naos received 112,000 stock options to purchase Protalix BioTherapeutics common stock at $2.59 per share and 56,000 restricted stock units, each representing one share of common stock, all granted on September 3, 2026.

What are the vesting terms of the new PLX stock options for Yaron Naos?

The options for 112,000 shares of Protalix BioTherapeutics common stock vest in 12 equal quarterly installments commencing on the date of grant, September 3, 2026, according to the footnote describing the vesting schedule.

How do the PLX restricted stock units granted to Yaron Naos vest?

The 56,000 restricted stock units granted to Yaron Naos vest in 12 equal quarterly installments beginning on September 3, 2026. Each vested unit entitles him, following vesting, to receive one share of Protalix BioTherapeutics common stock.

What is the exercise price and expiration date of the new PLX stock options?

The newly granted options allow Yaron Naos to purchase 112,000 shares of Protalix BioTherapeutics common stock at an exercise price of $2.59 per share and expire on September 3, 2036.

Does this PLX Form 4 indicate trades under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions; they are described as grants or awards of equity, not open-market trades.

What other option grants for PLX shares are referenced in the footnotes for Yaron Naos?

Footnotes reference additional options to purchase 60,000 shares at $5.60 expiring September 13, 2028; 122,656 shares at $3.59 expiring August 11, 2030; 340,000 shares at $1.03 expiring September 7, 2032; 100,000 shares at $1.10 expiring September 23, 2034; and 50,000 shares at $1.64 expiring September 3, 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:04 AM Accepted by SEC EDGAR 09/04/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Naos Yaron

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP & COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	09/03/2026		A		112,000		(1)	09/03/2036	Common Stock	112,000	$0	112,000(2)	D
Restricted Stock Units	(3)	09/03/2026		A		56,000		(4)	(4)	Common Stock	56,000	$0	56,000	D

Explanation of Responses:

1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

2. Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

	/s/ Joseph R. Magnas, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)